medigraphic.com
ISSN 0188-9796 (Impreso)

2005, Número 2

<< Anterior Siguiente >>

Rev Endocrinol Nutr 2005; 13 (2)


Péptidos anorexigénicos y su participación en la conducta alimentaria

Jaimes L, Cabrera-Wrooman A, Vilches A, Guzmán C, Camacho-Arroyo I

Idioma: Español
Referencias bibliográficas: 84
Paginas: 67-74
Archivo PDF: 138.88 Kb.


RESUMEN

La ingesta de alimentos y el gasto energético están regulados por un complejo sistema neuroendocrino que consiste de señales centrales, principalmente neuropéptidos, y de señales periféricas como la leptina. Varios neuropéptidos con acciones anorexigénicas (POMC, CART, CRH, TRH, a-MSH, GLP-1 y PYY) así como orexigénicas (NPY, AgRP y MCH) participan en este complejo sistema de regulación. El ayuno o la restricción de alimentos modifican a su vez la expresión de estos neuropéptidos, la cual también es regulada por la leptina. Esta revisión se enfoca a la participación de los principales neuropéptidos anorexigénicos en la regulación de la ingesta de alimento y del peso.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Horvath TL, Diano S, Tschop M. Brain circuits regulating energy homeostasis. Neuroscientist 2004; 10: 235-246.

  2. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184: 291-318.

  3. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, Vrang N, Larsen PJ, Hastrup S. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.

  4. Li G, Mobbs CV, Scarpace PJ. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 2003; 52: 1951-1957.

  5. Ramos EJ, Meguid MM, Campos AC, Coelho JC. Neuropeptide Y, alpha-melanocyte-stimulating hormone, and monoamines in food intake regulation. Nutrition 2005; 21: 269-279.

  6. Heinrichs SC, Menzaghi F, Pich EM, Hauger RL, Koob GF. Corticotropin-releasing factor in the paraventricular nucleus modulates feeding induced by neuropeptide Y. Brain Res 1993; 611: 18-24.

  7. Nillni EA, Sevarino KA. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr Rev 1999; 20: 599-648.

  8. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1: 271-272.

  9. Dube MG, Kalra SP, Kalra PS. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 1999; 842: 473-477.

  10. Qu D, Ludwig DS, Gammeltoft S, Piper M, Pelleymounter MA, Cullen MJ, Mathes WF, Przypek R, Kanarek R, Maratos-Flier E. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243-247.

  11. Hakansson ML, Brown H, Ghilardi N, Skoda RC, Meister B. Leptin receptor immunoreactivity in chemically defined target neurons of the hypothalamus. J Neurosci 1998; 18: 559-572.

  12. Khachaturian H, Lewis ME, Haber SN, Akil H, Watson SJ. Proopiomelanocortin peptide immunocytochemistry in rhesus monkey brain. Brain Res Bull 1984; 13: 785-800.

  13. Swart I, Jahng JW, Overton JM, Houpt TA. Hypothalamic NPY, AGRP, and POMC mRNA responses to leptin and refeeding in mice. Am J Physiol Regul Integr Comp Physiol 2002; 283: R1020-1026.

  14. Koegler FH, Grove KL, Schiffmacher A, Smith MS, Cameron JL. Central melanocortin receptors mediate changes in food intake in the rhesus macaque. Endocrinology 2001; 142: 2586-2592.

  15. Adage T, Scheurink AJ, de Boer SF, de Vries K, Konsman JP, Kuipers F, Adan RA, Baskin DG, Schwartz MW, van Dijk G. Hypothalamic, metabolic, and behavioral responses to pharmacological inhibition of CNS melanocortin signaling in rats. J Neurosci 2001; 21: 3639-3645.

  16. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001; 61: 1432-1438.

  17. Fehm HL, Smolnik R, Kern W, McGregor GP, Bickel U, Born J. The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans. J Clin Endocrinol Metab 2001; 86: 1144-1148.

  18. Larsen LH, Echwald SM, Sorensen TI, Andersen T, Wulff BS, Pedersen O. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab 2005; 90: 219-224.

  19. Fetissov SO, Hallman J, Oreland L, Af Klinteberg B, Grenback E, Hulting AL, Hokfelt T. Autoantibodies against alpha-MSH, ACTH, and LHRH in anorexia and bulimia nervosa patients. Proc Natl Acad Sci USA 2002; 99: 17155-17160.

  20. Hillebrand JJ, de Wied D, Adan RA. Neuropeptides, food intake and body weight regulation: a hypothalamic focus. Peptides 2002; 23: 2283-2306.

  21. Douglass J, Daoud S. Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. Gene 1996; 169: 241-245.

  22. Aja S, Schwartz GJ, Kuhar MJ, Moran TH. Intracerebroventricular CART peptide reduces rat ingestive behavior and alters licking microstructure. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1613-1619.

  23. Aja S, Sahandy S, Ladenheim EE, Schwartz GJ, Moran TH. Intracerebroventricular CART peptide reduces food intake and alters motor behavior at a hindbrain site. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1862-1867.

  24. Hunter RG, Kuhar MJ. CART peptides as targets for CNS drug development. Curr Drug Targets CNS Neurol Disord 2003; 2: 201-205.

  25. del Giudice EM, Santoro N, Cirillo G, D’Urso L, Di Toro R, Perrone L. Mutational screening of the CART gene in obese children: identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and cosegregating with obesity phenotype in a large family. Diabetes 2001; 50: 2157-2160.

  26. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR, Bloom SR. Characterization of glucagon-like peptide-1-(7-36)amide in the hypothalamus. Brain Res 1989; 502: 325-331.

  27. Miki T, Minami K, Shinozaki H, Matsumura K, Saraya A, Ikeda H, Yamada Y, Holst JJ, Seino S. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like Peptide-1 on insulin secretion and gut motility. Diabetes 2005; 54: 1056-1063.

  28. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-856.

  29. Donahey JC, van Dijk G, Woods SC, Seeley RJ. Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats. Brain Res 1998; 779: 75-83.

  30. Meeran K, O’Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999; 140: 244-250.

  31. Sarkar S, Fekete C, Legradi G, Lechan RM. Glucagon like peptide-1 (7-36) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res 2003; 985: 163-168.

  32. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Caceres J, Desco M, Pozo MA, Blazquez E. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 2005; 92: 798-806.

  33. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.

  34. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction. Int J Obes Relat Metab Disord 2001; 25: 1206-1214.

  35. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23: 304-311.

  36. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.

  37. Uckaya G, Delagrange P, Chavanieu A, Grassy G, Berthault MF, Ktorza A, Cerasi E, Leibowitz G, Kaiser N. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue. J Endocrinol 2005; 184: 505-513.

  38. Burgus R, Dunn TF, Desiderio D, Vale W, Guillemin R. [Synthetic polypeptide derivatives with TRF hypophysiotropic activity. New data]. C R Acad Sci Hebd Seances Acad Sci D 1969; 269: 226-228.

  39. Harris AR, Christianson D, Smith MS, Fang SL, Braverman LE, Vagenakis AG. The physiological role of thyrotropin-releasing hormone in the regulation of thyroid-stimulating hormone and prolactin secretion in the rat. J Clin Invest 1978; 61: 441-448.

  40. Morley JE. Neuroendocrine control of thyrotropin secretion. Endocr Rev 1981; 2: 396-436.

  41. Kakucska I, Rand W, Lechan RM. Thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is dependent upon feedback regulation by both triiodothyronine and thyroxine. Endocrinology 1992; 130: 2845-2850.

  42. Tang F, Man WS. The regional distribution of thyrotropin releasing hormone, leu-enkephalin, met-enkephalin, substance P, somatostatin and cholecystokinin in the rat brain and pituitary. Neuropeptides 1991; 19: 287-292.

  43. Calza L, Giardino L, Ceccatelli S, Zanni M, Elde R, Hokfelt T. Distribution of thyrotropin-releasing hormone receptor messenger RNA in the rat brain: an in situ hybridization study. Neuroscience 1992; 51: 891-909.

  44. Heuer H, Ehrchen J, Bauer K, Schafer MK. Region-specific expression of thyrotrophin-releasing hormone-degrading ectoenzyme in the rat central nervous system and pituitary gland. Eur J Neurosci 1998; 10: 1465-1478.

  45. Vogel RA, Cooper BR, Barlow TS, Prange AJ Jr, Mueller RA, Breese GR. Effects of thyrotropin-releasing hormone on locomotor activity, operant performance and ingestive behavior. J Pharmacol Exp Ther 1979; 208: 161-168.

  46. Blake NG, Eckland DJ, Foster OJ, Lightman SL. Inhibition of hypothalamic thyrotropin-releasing hormone messenger ribonucleic acid during food deprivation. Endocrinology 1991; 129: 2714-2718.

  47. Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332: 621-628.

  48. van Haasteren GA, Linkels E, Klootwijk W, van Toor H, Rondeel JM, Themmen AP, de Jong FH, Valentijn K, Vaudry H, Bauer K et al. Starvation-induced changes in the hypothalamic content of prothyrotrophin-releasing hormone (proTRH) mRNA and the hypothalamic release of proTRH-derived peptides: role of the adrenal gland. J Endocrinol 1995; 145: 143-153.

  49. Legradi G, Emerson CH, Ahima RS, Flier JS, Lechan RM. Leptin prevents fasting-induced suppression of prothyrotropin-releasing hormone messenger ribonucleic acid in neurons of the hypothalamic paraventricular nucleus. Endocrinology 1997; 138: 2569-2576.

  50. Lesem MD, Kaye WH, Bissette G, Jimerson DC, Nemeroff CB. Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa. Biol Psychiatry 1994; 35: 48-53.

  51. Smith MA, Kling MA, Whitfield HJ, Brandt HA, Demitrack MA, Geracioti TD, Chrousos GP, Gold PW. Corticotropin-releasing hormone: from endocrinology to psychobiology. Horm Res 1989; 31: 66-71.

  52. Krahn DD, Gosnell BA, Majchrzak MJ. The anorectic effects of CRH and restraint stress decrease with repeated exposures. Biol Psychiatry 1990; 27: 1094-1102.

  53. Weninger SC, Muglia LJ, Jacobson L, Majzoub JA. CRH-deficient mice have a normal anorectic response to chronic stress. Regul Pept 1999; 84: 69-74.

  54. Wang C, Mullet MA, Glass MJ, Billington CJ, Levine AS, Kotz CM. Feeding inhibition by urocortin in the rat hypothalamic paraventricular nucleus. Am J Physiol Regul Integr Comp Physiol 2001; 280: R473-480.

  55. Cullen MJ, Ling N, Foster AC, Pelleymounter MA. Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 2001; 142: 992-999.

  56. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000; 24: 410-414.

  57. Duclos M, Corcuff JB, Roger P, Tabarin A. The dexamethasone-suppressed corticotrophin-releasing hormone stimulation test in anorexia nervosa. Clin Endocrinol (Oxf) 1999; 51: 725-731.

  58. Hotta M, Shibasaki T, Masuda A, Imaki T, Demura H, Ling N, Shizume K. The responses of plasma adrenocorticotropin and cortisol to corticotropin-releasing hormone (CRH) and cerebrospinal fluid immunoreactive CRH in anorexia nervosa patients. J Clin Endocrinol Metab 1986; 62: 319-324.

  59. Houseknecht KL, Baile CA, Matteri RL, Spurlock ME. The biology of leptin: a review. J Anim Sci 1998; 76: 1405-1420.

  60. Janeckova R. The role of leptin in human physiology and pathophysiology. Physiol Res 2001; 50: 443-459.

  61. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.

  62. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-495.

  63. Kaibara A, Moshyedi A, Auffenberg T, Abouhamze A, Copeland EM 3rd, Kalra S, Moldawer LL. Leptin produces anorexia and weight loss without inducing an acute phase response or protein wasting. Am J Physiol 1998; 274: R1518-1525.

  64. Okamoto S, Kimura K, Saito M. Anorectic effect of leptin is mediated by hypothalamic corticotropin-releasing hormone, but not by urocortin, in rats. Neurosci Lett 2001; 307: 179-182.

  65. Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM, Emerson CH, Lechan RM. Alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. J Neurosci 2000; 20: 1550-1558.

  66. Nillni EA, Vaslet C, Harris M, Hollenberg A, Bjorbak C, Flier JS. Leptin regulates prothyrotropin-releasing hormone biosynthesis. Evidence for direct and indirect pathways. J Biol Chem 2000; 275: 36124-36133.

  67. Harris M, Aschkenasi C, Elias CF, Chandrankunnel A, Nillni EA, Bjoorbaek C, Elmquist JK, Flier JS, Hollenberg AN. Transcriptional regulation of the thyrotropin-releasing hormone gene by leptin and melanocortin signaling. J Clin Invest 2001; 107: 111-120.

  68. Guo F, Bakal K, Minokoshi Y, Hollenberg AN. Leptin signaling targets the thyrotropin-releasing hormone gene promoter in vivo. Endocrinology 2004; 145: 2221-2227.

  69. Geldszus R, Mayr B, Horn R, Geisthovel F, von zur Muhlen A, Brabant G. Serum leptin and weight reduction in female obesity. Eur J Endocrinol 1996; 135: 659-662.

  70. Misra M, Miller KK, Kuo K, Griffin K, Stewart V, Hunter E, Herzog DB, Klibanski A. Secretory Dynamics of Leptin in Adolescent Girls with Anorexia Nervosa and Healthy Adolescents. Am J Physiol Endocrinol Metab 2005.

  71. Haas V, Onur S, Paul T, Nutzinger DO, Bosy-Westphal A, Hauer M, Brabant G, Klein H, Muller MJ. Leptin and body weight regulation in patients with anorexia nervosa before and during weight recovery. Am J Clin Nutr 2005; 81: 889-896.

  72. Brown DR, Berkowitz DE, Breslow MJ. Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab 2001; 86: 162-166.

  73. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002; 109: 1345-1350.

  74. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346: 570-578.

  75. Wolfe BE, Jimerson DC, Orlova C, Mantzoros CS. Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin Endocrinol (Oxf) 2004; 61: 332-338.

  76. Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibanski A. Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 3486-3495.

  77. Ekblad E, Sundler F. Distribution of pancreatic polypeptide and peptide YY. Peptides 2002; 23: 251-261.

  78. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 1999; 438: 299-306.

  79. Soffer EE, Adrian TE, Launspach J, Zimmerman B. Meal-induced secretion of gastrointestinal regulatory peptides is not affected by sleep. Neurogastroenterol Motil 1997; 9: 7-12.

  80. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.

  81. Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O’Rahilly S. Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 2003; 311: 915-919.

  82. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 2003; 88: 3989-3992.

  83. Monteleone P, Martiadis V, Rigamonti AE, Fabrazzo M, Giordani C, Muller EE, Maj M. Investigation of peptide YY and ghrelin responses to a test meal in bulimia nervosa. Biol Psychiatry 2005; 57: 926-931.

  84. Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, Fernandez-Represa JA. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002; 12: 324-327.




2020     |     www.medigraphic.com